other_material
confidence high
sentiment positive
materiality 0.70
AEON Biopharma reports Q1 cash $6.2M; FDA supports ABP-450 biosimilar plan; debt cut >90%
AEON Biopharma, Inc.
- FDA BPD Type 2a meeting deemed AEON's analytical similarity strategy reasonable for 351(k) pathway.
- Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by >90%.
- Appointed John Bencich as CFO, bringing 25+ years of corporate and capital markets experience.
- Cash and cash equivalents $6.2M at March 31, plus $0.9M April ATM; funds operations into Q3 2026.
- Plans BPD Type 2b meeting in H2 2026 to discuss remaining biosimilar development program.
item 2.02item 9.01